CLAIMS

1. Use of a heterocyclic derivative corresponding to the formula

5

in the form of diastereoisomers or any combinations of these forms,

in which R represents the hydrogen atom, a (C_1-C_6) alkyl, arylalkyl or -C(O)R' radical in which R' represents a heterocycloalkyl, (C_1-C_6) alkyl, aryl or aralkyl radical;

the alkyl, aryl or heterocycloalkyl radicals being optionally substituted by one or more identical or different substituants chosen from: (C₁-C₆)alkyl, hydroxy, (C₁-C₆)alkoxy, nitro, cyano, halogen or -NR₁R₂;

 R_1 and R_2 represent, independently, a hydrogen atom or an (C_1-C_6) alkyl radical, or R_1 and R_2 form together with the nitrogen atom to which they are attached an optionally substituted heterocycle,

- 15 for the preparation of a medicament intended to prevent and/or treat hearing loss.
 - 2. Use according to claim 1, characterized in that R represents –C(O)R'.
 - 3. Use according to claim 2, characterized in that R' represents an alkyl radical.
 - 4. Use according to claim 3, characterized in that R represents -C(O)-CH₃.
 - 5. Use according to claim 1, characterized in that R represents hydrogen.

6. Use according to one of the preceding claims, characterized in that the compound (I) has the formula

$$\begin{array}{c|c} S \\ \hline \\ N \\ \hline \\ H \\ \end{array} \begin{array}{c} O \\ \hline \\ O \\ \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} O \\ \hline \\ \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} O \\ \hline$$

7. Use according to claim 6, characterized in that the compound (I) has the formula

$$\begin{array}{c|c} S \\ \hline \\ N \\ \hline \\ H \\ \end{array} \begin{array}{c} O \\ \hline \\ OR \\ \end{array} \begin{array}{c} O \\ \hline \\ OR \\ \end{array} \begin{array}{c} (I_{A1}) \\ \end{array}$$

5

8. Use according to claim 6, characterized in that the compound (I) has the formula

$$\begin{array}{c|c} S \\ \hline \\ N \\ \hline \\ N \\ \end{array}$$

9. Use according to one of claims 1 to 5, characterized in that the compound (I) has the formula

$$\begin{array}{c|c} S \\ \hline \\ N \\ \hline \\ H \\ \end{array} \begin{array}{c} O \\ \hline \\ OR \\ \end{array} \begin{array}{c} O \\ \hline \\ (I_B) \\ \end{array}$$

10

10. Use according to claim 8, characterized in that the compound (I) has the formula

11. Use according to claim 8, characterized in that the compound (I) has the formula

$$\begin{array}{c|c} S \\ \hline \\ N \\ \hline \\ N \\ \hline \\ O \\ \hline \\ \end{array}$$

- 12. Use according to one of the preceding claims, characterized in that the derivative (I) is administered in a pre-treatment.
 - 13. Use according to one of claims 1 to 11, characterized in that the derivative (I) is administered in a post-treatment.
- 14. Use according to one of the preceding claims, for the preparation of a medicament intended to prevent and/or treat hearing loss following the administration of a medicament.
 - 15. Use according to claim 14, following the administration of another medicament chosen from antibiotics, anti-cancer drugs, non-steroidal anti-inflammatory agents, diuretics, antiulceratives, anticonvulsant agents.
 - 16. Use according to claim 15, following the administration of an antibiotic.
- 15 17. Use according to claim 16, characterized in that the antibiotic is gentamicin.
 - 18. Use according to one of claims 1 to 13, for the preparation of a medicament intended to prevent and/or treat hearing loss following presbycusis.
 - 19. Use according to one of claims 1 to 13, for the preparation of a medicament intended to prevent and/or treat hearing loss following an acoustic traumatism.

- 20. Use according to claim 19, characterized in that the compound (I) is administered in the 7 hours and preferably in the hour following the acoustic traumatism.
- 21. Use according to one of the preceding claims, characterized in that the compound (I) is combined with at least one other substance with pharmaceutical activity.

5

- 22. Use according to one of the preceding claims, characterized in that the compound (I) is combined with at least one other substance with pharmaceutical activity which is able to prevent and/or treat hearing loss or to prevent and/or treat any pathologies associated with hearing loss.
- 23. Use according to one of claims 21 to 22, characterized in that the other substance with pharmaceutical activity is chosen from: antioxidants, calpain inhibitors, peripheral vasodilitators, agonists or antagonists of the NMDA receptor and peptide inhibitors of c-Jun N-terminal kinase.
- 24. Product comprising a heterocyclic derivative of formula (I) as defined in one of claims 1 to 11, and at least one substance with therapeutic activity, as a combination product for a use which is simultaneous, separate or spread over time in order to prevent and/or treat hearing loss.
 - 25. Product according to claim 24, to prevent and/or treat hearing loss following the administration of a medicament.
- 26. Product according to claim 25, to prevent and/or treat hearing loss following the administration of an antibiotic, and preferably gentamicin.
 - 27. Product according to claim 24, to prevent and/or treat hearing loss following presbycusis.
- 28. Product according to claim 24, to prevent and/or treat hearing loss following an acoustic traumatism.
 - 29. As a medicament, a product as defined in one of claims 24 to 28.